Delivery Order SPE2DB22D3009-SPE2DB25FBB53
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,373.44 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin pump pods. The contract, issued on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a firm fixed-price procurement with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $13,284.02 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Gen 5 pods, with an ultimate completion date of August 5, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $36,377.71 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 insulin infusion pump pods. This firm fixed-price delivery order was competitively awarded without a set-aside designation and carries an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,951.77 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5), with a completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,715.24 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 insulin infusion pump pods (Generation 5) with a completion date of August 28, 2025. This non-competed delivery order utilizes firm fixed pricing and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is positioned as a critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $7,950.79 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5), 5-count units, with performance in Conshohocken, Pennsylvania and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive process, representing a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $1,531.79 to AmerisourceBergen Drug Corp for OmniPod 5 with Dexcom G7 continuous glucose monitoring system (Generation 5) on June 4, 2025, with completion expected by June 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,202.14 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Gen 5 insulin infusion pods. The contract employs firm fixed pricing with no set-aside designation and is scheduled for completion by June 20, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive...
- The Defense Logistics Agency awarded a $50,317.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 insulin infusion pods. The contract, issued on August 26, 2025, with completion by August 27, 2025, represents a non-competitive delivery order without set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order falls under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,138.73 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The products will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBB53Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,658.80 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods, with an ultimate completion date of July 23, 2025. This non-set-aside, firm fixed price contract represents a competitively awarded delivery order supporting federal medical supply needs. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The OmniPod 5 insulin delivery system with integrated Dexcom continuous glucose monitoring represents a specialized medical device component that supports diabetes management across the Defense Health Agency and other federal healthcare systems. As a prime vendor on the DLA's Pharmaceutical Prime Vendor Global Program, AmerisourceBergen demonstrates the capability to fulfill diverse medical supply requirements through competitive federal contracting, ranging from small-value transactions to substantial orders exceeding $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 7/22/25 |